Treatment Patterns and Recommendations for Improving the Management of Hepatocellular Carcinoma in Saudi Arabia
Rattachement africain : sa, Égypte. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Hepatocellular carcinoma (HCC) is the sixth most common type of cancer in the world associated with high morbidity and mortality. Despite being a significant healthcare burden there is limited information on the unmet needs and current treatment practices for intermediate and advanced-stage HCC in Saudi Arabia. This article analyzes the gaps and provides expert consensus on the management strategies for unresectable HCC in Saudi Arabia. A pre-meeting online questionnaire, comprising 20 objective questions about the treatment landscape and diagnosis of HCC in Saudi Arabia, was distributed to experts in the field of HCC management. An advisory board meeting including a panel of 13 experts was held in September 2022 where the responses to the survey questionnaire were reviewed and discussed. The survey results and experts' discussion highlighted the growing incidence of liver cancer in Saudi Arabia. HCC comprised the majority of all liver cancer cases due to rising rates of chronic viral infections and lifestyle-related risk factors. Most physicians in Saudi Arabia follow the Barcelona Clinic Liver Cancer guidelines as a prognostic tool for the detection and staging of patients with HCC. Most of the patients with HCC in Saudi Arabia are diagnosed in the intermediate or advanced stages with poor prognoses and limited therapeutic options. Establishing evidence-based surveillance techniques, a multidisciplinary approach to diagnosis, and better accessibility of treatment options is vital for the management of HCC in Saudi Arabia.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Treatment Patterns and Recommendations for Improving the Management of Hepatocellular Carcinoma in Saudi Arabia
- Date Crossref
- 01/02/2024
- Éditeur
- Informa UK Limited
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
National Guard Health Affairs Department of Medical Oncology pays non établi dans la noticeÉtablissement de santé
-
King Faisal Specialist Hospital & Research Centre pays non établi dans la noticeÉtablissement de santé
-
King Fahad Specialist Hospital Department of Medical Oncology pays non établi dans la noticeÉtablissement de santé
-
King Fahd Medical City pays non établi dans la noticeOrganisme public
-
Riyadh Armed Forces Hospital pays non établi dans la noticeÉtablissement de santé
-
Minia University Department of Medicine Minia University, Égypte (code pays fourni par la source)Université ou école supérieure
-
King Abdullah Medical City pays non établi dans la noticeÉtablissement de santé
-
King Khalid National Guard Hospital Abdulaziz Medical City Department of Oncology pays non établi dans la noticeÉtablissement de santé
-
King Faisal Specialist Hospital and Research Centre Department of Radiology pays non établi dans la noticeStructure de recherche
-
Department of Medical Oncology pays non établi dans la noticeInstitution
-
Prince Sultan Military Medical City Hospital Department of Oncology pays non établi dans la noticeÉtablissement de santé
-
Department of Gastroenterology and Hepatology pays non établi dans la noticeInstitution
Department of Medical Oncology — National Guard Health Affairs, King Faisal Specialist Hospital & Research Centre et Department of Medical Oncology — King Fahad Specialist Hospital, avec 9 autres affiliations. Pays d’affiliation : Égypte.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.